作为一家主攻肿瘤免疫学及免疫性疾病疗法的医药公司,和铂医药-B今日在早盘出现大涨11.19%的行情,吸引市场关注。消息面上,该公司公布2024年度业绩超预期,引发市场热捧。
和铂医药-B在公告中透露,预计2024年度溢利(税后利润)将达人民币730万元至2200万元,同时经营现金流为净流入2.2亿元人民币,创下现金溢利的历史新高水平。这一业绩表现远超市场预期,凸显了公司蓬勃的业务增长势头和高效的运营管理水平。
公司盈利能力主要受以下几方面因素推动:一是通过与众多全球性药企及生物技术公司保持良好的战略合作关系,公司独特的业务模式加速了收入增长;二是公司经常性收入来源,如基于技术平台的研究收入、合作项目的里程碑付款等在2024年持续增长;三是公司有效控制成本,精细化运营管理。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.